Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Date:6/1/2009

cute exacerbation of edema-associated symptoms.

Brain Scans and Preclinical Studies

Celtic Pharma has been able to collect over 500 brain scans from patients on these XERECEPT(R) studies, and has submitted them to an independent center for blinded review. This review is ongoing, and to date the scans from 93 patients have been evaluated. The review indicates 75 percent of these patients with primary and metastatic brain tumors appear to have stable disease after six months of treatment with XERECEPT(R), with nine percent of these patients showing reductions in tumor size of 50 percent or greater.

Celtic Pharma also announced today the results from several preclinical studies of XERECEPT(R) in established brain tumor models, in addition to assessment of angiogenesis inhibition potential. These placebo-controlled studies were conducted at Memorial Sloan Kettering Cancer Center in New York as well as Duke University and the Piedmont Research Center, both in North Carolina. The tumor assessment studies were conducted using both pediatric and adult human brain tumor xenografts. The mouse tumor models demonstrated statistically significant tumor regression and prolongation of survival following treatment with XERECEPT(R). XERECEPT(R) also demonstrated significant dose-related angiogenesis inhibition, comparable in this model, as assessed by the laboratory, to results seen with Sutent.(R) These preclinical findings demonstrate that XERECEPT(R) has direct antitumor and angiogenesis inhibition activity, in these models.

John Mayo, co-Managing General Partner of Celtic Pharma, said "This product has great steroid-sparing potential. The anti tumor effects observed in preclinical studies also open up further valuable market opportunities."

XERECEPT(R) is an investigational new drug under development as a steroid-sparing alternative to dexamethasone for patients with primary
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 Social-Engineer, ... social engineering announced today it will host a complimentary ... The webinar will reveal the final outcome of the ... DEF CON 22 in Las Vegas and explore how ... social engineering attacks. To register for the webinar ...
(Date:10/2/2014)... The Business Intelligence Group today ... for Business program. The BIG Awards specialize in ... judging process scored by well-known and experienced leaders ... winners this year epitomize what is going right ... the Business Intelligence Group. “The sheer amount of ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product ... great appreciation from the global customers in the past ... make more excellent items. All its online workers are ... clients. , The company has recently added a ... website. Furthermore, the company’s marketing specialist has announced that ...
(Date:10/2/2014)... Maureen Salamon ... News) -- Middle-aged women with a neurotic personality style ... developing Alzheimer,s disease, new research suggests. Tracking 800 ... those who were most anxious, jealous and moody -- ... stress had double the risk of developing Alzheimer,s compared ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2
... The Vatican has yet again been forced to revise ... a foreign trip. En route to Cameroon on March 17, ... of HIV. A transcript of the pope,s comments on the ... "risked" aggravating the problem.Jon O,Brien, president of Catholics for Choice, ...
... found levels of certain cytokines spiked during disease stage ... South Africa recently had the rare opportunity to follow ... and recovery in a 29-year-old lab worker who had ... particular, the researchers followed the trajectory of cytokines, a ...
... hypertension, obesity, study found , , WEDNESDAY, March 18 (HealthDay News) ... than whites, a long-running study shows. , "What we found ... and it is not a rare occurrence," said Dr. Kirsten ... issue of the New England Journal of Medicine . ...
... the care needs of a child dependent on technology is ... upon mothers to help everyone in the family adjust. However, ... the challenges of raising these children, a research study from ... its cues from me," one mother told Valerie Toly, PhD, ...
... clinicians to identify study participants could compromise the recruitment ... to address this conflict of interest in their Institutional ... associate professor of law at Georgia State University, studied ... 117 medical schools that received National Institutes of Health ...
... March 18 Cogdell Spencer Inc. (NYSE: ... has declared a quarterly dividend of $0.225 per common share ... March 31, 2009. The dividend covers the first quarter ... Cogdell Spencer Inc. (NYSE: CSA ) is a ...
Cached Medicine News:Health News:Pope Not Infallible on Condoms 2Health News:Course of West Nile Infection Charted 2Health News:Course of West Nile Infection Charted 3Health News:High Rate of Early Heart Failure Seen in Blacks 2Health News:High Rate of Early Heart Failure Seen in Blacks 3Health News:Mothers have key role in family life for children with technology dependencies 2Health News:Conflicts of interest in clinical research 2Health News:Cogdell Spencer Inc. Declares Quarterly Dividend 2
Large. 2.5 mm diameter blade. Angled up 45 degrees. Round handle....
3 mm curved blade. Round handle....
9 mm blade....
Storz Ear Knife Handle....
Medicine Products: